Seiichi Shinji

Dr. Seiichi Shinji

Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
KTKohki Takeda
Kohki Takeda
TYTakeshi Yamada
Takeshi Yamada
GTGoro Takahashi
Goro Takahashi
TITakuma Iwai
Takuma Iwai
KUKoji Ueda
Koji Ueda
HYHiroshi Yoshida
Hiroshi Yoshida
We recruited 56 colorectal cancer patients and compared the mutational spectrum of tumor tissue DNA, circulating cell‐free DNA (ccfDNA) and circulating tumor cell (CTC) DNA (ctcDNA) to evaluate the potential of liquid biopsy to detect heterogeneity of cancer. Tumor tissue DNA, ccfDNA, and ctcDNA were extracted from each patient and analyzed using next‐generation sequencing (NGS) and digital PCR. To maximize yields of CTC, three antibodies were used in the capture process. From 34 untreated patients, 53 mutations were detected in tumor tissue DNA using NGS. Forty‐seven mutations were detected in ccfDNA, including 20 not detected in tissues. Sixteen mutations were detected in ctcDNA, including five not detected in tissues. In 12 patients (35.3%), mutations not found in tumor tissues were detected by liquid biopsy: nine (26.5%) in ccfDNA only and three (8.8%) in ctcDNA only. Combination analysis of the two liquid biopsy samples increased the sensitivity to detect heterogeneity. From 22 stage IV patients with RAS mutations in their primary tumors, RAS mutations were detected in 14 (63.6%) ccfDNA and in eight (36.4%) ctcDNA using digital PCR. Mutations not detected in primary tumors can be identified in ccfDNA and in ctcDNA, indicating the potential of liquid biopsy in complementing gene analysis. Combination analysis improves sensitivity. Sensitivity to detect cancer‐specific mutations is higher in ccfDNA compared with ctcDNA.

17 July 2018 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
Seiichi ShinjiSeiichi Shinji
Seiichi Shinji
YUYoshibumi Ueda
Yoshibumi Ueda
TYTakeshi Yamada
Takeshi Yamada
MKMichihiro Koizumi
Michihiro Koizumi
YYYasuyuki Yokoyama
Yasuyuki Yokoyama
HYHiroshi Yoshida
Hiroshi Yoshida
Anastomotic leakage (AL) is the most serious and common complication of surgery for rectal cancer, and associated risk factors remain unknown despite developments in laparoscopic surgery. The present study aimed to determine risk factors for AL after laparoscopic anterior resection (AR) of rectal cancer. This retrospective cohort study extracted information from a prospective database of all consecutive colorectal resections that proceeded at Nippon Medical School Hospital between January 2011 and December 2015 (n = 865). We identified 154 patients with rectal cancer treated by elective laparoscopic AR with anastomosis using primary double-stapling. Clinical variables and comorbidity, habits, and surgery-related variables were assessed by univariate and multivariate analyses to determine preoperative risk factors for clinical AL. The overall rate of clinical AL was 11.7% (18 of 154 patients), and 5 (27.8%) of 18 patients required revised laparotomy. Data from males were analyzed because AL occurred only in males. Univariate analysis of male patients (n = 100) significantly associated preoperative creatinine values (p = 0.03) and a history of ischemic heart disease (IHD) (p = 0.012) with AL. The frequency of AL tended to increase (p = 0.06) when patients had low AR (p = 0.06) and transanal drainage. Having AL significantly prolonged hospital stays compared with patients without leakage (36.2 vs. 11.1 days; p < 0.01). Multivariate analysis identified a history of IHD (odds ratio [OR], 4.73; 95% confidence interval [CI], 1.27–17.5; p = 0.025] as an independent risk factor for AL. Male sex and a history of IHD are possible risk factors for AL after elective laparoscopic rectal cancer surgery.

31 January 2024 in Cancer Science
Verified
Journal Article
Open access
TMToshimitsu Miyasaka
Toshimitsu Miyasaka
TYTakeshi Yamada
Takeshi Yamada
KUKay Uehara
Kay Uehara
HSHiromichi Sonoda
Hiromichi Sonoda
AMAkihisa Matsuda
Akihisa Matsuda
HYHiroshi Yoshida
Hiroshi Yoshida
A significant association exists between the gut microbiome and colorectal carcinogenesis, as well as cancer progression. It has been reported that Escherichia coli (E. coli) containing polyketide synthetase (pks) island contribute to colorectal carcinogenesis by producing colibactin, a polyketide‐peptide genotoxin. However, the functions of pks+ E. coli in initiation, proliferation, and metastasis of colorectal cancer (CRC) remain unclear. We investigated the clinical significance of pks+ E. coli to clarify its functions in CRC. This study included 413 patients with CRC. Pks+ E. coli of tumor tissue and normal mucosal tissue were quantified using droplet digital PCR. Pks+ E. coli was more abundant in Stages 0–I tumor tissue than in normal mucosal tissue or in Stages II–IV tumor tissue. High abundance of pks+ E. coli in tumor tissue was significantly associated with shallower tumor depth (hazard ratio [HR] = 5.0, 95% confidence interval [CI] = 2.3–11.3, p < 0.001) and absence of lymph node metastasis (HR = 3.0, 95% CI = 1.8–5.1, p < 0.001) in multivariable logistic analyses. Pks+ E. coli‐low and ‐negative groups were significantly associated with shorter CRC‐specific survival (HR = 6.4, 95% CI = 1.7–25.6, p = 0.005) and shorter relapse‐free survival (HR = 3.1, 95% CI = 1.3–7.3, p = 0.01) compared to the pks+ E. coli‐high group. Pks+ E. coli was abundant in Stages 0–I CRC and associated with CRC prognosis. These results suggest that pks+ E. coli might contribute to carcinogenesis of CRC but might not be associated with tumor progression.

1 December 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
RORyo Ohta
Ryo Ohta
TYTakeshi Yamada
Takeshi Yamada
HSHiromichi Sonoda
Hiromichi Sonoda
AMAkihisa Matsuda
Akihisa Matsuda
Seiichi ShinjiSeiichi Shinji
Seiichi Shinji
HYHiroshi Yoshida
Hiroshi Yoshida

1 November 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
HSHiromichi Sonoda
Hiromichi Sonoda
TYTakeshi Yamada
Takeshi Yamada
AMAkihisa Matsuda
Akihisa Matsuda
RORyo Ohta
Ryo Ohta
Seiichi ShinjiSeiichi Shinji
Seiichi Shinji
HYHiroshi Yoshida
Hiroshi Yoshida

22 November 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KMKeigo Mitsui
Keigo Mitsui
MYMasaoki Yonezawa
Masaoki Yonezawa
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
Seiichi ShinjiSeiichi Shinji
Seiichi Shinji
KGKatya Gudis
Katya Gudis
CSChoitsu Sakamoto
Choitsu Sakamoto
The ErbB family consists of four proteins including (EGFR)/ErbB1, ErbB2, ErbB3, and ErbB4, and plays a crucial role in the promotion of multiple tumorigenic processes. In addition to the traditional pathways of EGFR signaling, EGFR translocates to the nucleus and acts as a transcription factor in the proliferation of cancer cells. Heregulin is known as both an ErbB3 and an ErbB4 ligand. This study aimed to investigate the expression of heregulin and its relevant EGFR family members as well as their phosphorylated forms in human colorectal cancer (CRC) tissues and to determine the relationship between their expression and clinicopathological factors including patient prognosis. We analyzed the effects of exogenous heregulin on ErbB2, ErbB3 and ErbB4 phosphorylation in Caco-2, DLD-1, and HCT 116 colon cancer cell lines by western blot analysis. We examined 155 surgical resections from colorectomy patients. Cellular localization of ErbB1-4, their phosphorylated forms and heregulin protein was analyzed in CRC surgical resections by immunohistochemical analysis. Immunohistochemical results were compared with clinicopathological factors and patient prognosis. Phosphorylated ErbB2 (pErbB2) and phosphorylated ErbB3 (pErbB3) were detected in both nuclear and cytosolic fractions of Caco-2 and DLD-1 cells stimulated by exogenous heregulin. Whereas, phosphorylated ErbB4 (pErbB4) was detected only in cytosolic fractions of HCT 116 cells stimulated by exogenous heregulin. Phosphorylated EGFR (pEGFR) immunoreactivity was observed in the cytoplasm and nuclei of cancer cells, whereas the pattern of EGFR staining was membranous and cytoplasmic. Subcellular localization of pErbB2, cytoplasmic, membranous, or nuclear, varied among cases. pErbB3 immunoreactivity was exclusively observed in the nuclei of cancer cells. pErbB4 immunoreactivity was observed in the cell membrane of cancer cells. Statistically, heregulin immunoreactivity correlated with pErbB2 and pErbB4 expression. In multivariate analysis for disease free survival, lymph node status, pErbB3 and pErbB4 expression retained independent prognostic significance. In multivariate analysis for overall survival, lymph node status, pEGFR and pErbB4 retained independent prognostic significance. ErbB2 and ErbB3 phosphorylated by heregulin localized in the nucleus of CRC cells. Phosphorylated ErbB1-4 and heregulin contribute to poorer patient prognosis in CRC. This heregulin-ErbB family member autocrine loop may be a candidate for targeted treatment of CRC.